SCHEMBL5808264

SCHEMBL5808264

COC(=O)C(CO)NC(C)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 2/20 0.44
THRB P10828 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
NFKB1 P19838 1/20 0.43
PTGS2 P35354 1/20 0.43
THPO P40225 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
MME P08473 2/20 0.43
ALDH1A1 P00352 2/20 0.42
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18055691 1.00 TGFBR1 (0.44) TGFBR1THRBSMN1; SMN2KDM4EMAPT
SCHEMBL5808266 1.00 TGFBR1 (0.44) TGFBR1THRBSMN1; SMN2KDM4EMAPT
SCHEMBL14409746 0.86 THRB (0.50) TGFBR1THRBSMN1; SMN2KDM4EMAPT
SCHEMBL14409743 0.84 MME (0.41) TGFBR1THRBSMN1; SMN2KDM4EMAPT
SCHEMBL12064041 0.84 SMN1; SMN2 (0.45) THRBSMN1; SMN2KDM4EMAPTALOX15
SCHEMBL12064029 0.84 SMN1; SMN2 (0.45) THRBSMN1; SMN2KDM4EMAPTALOX15
SCHEMBL12064309 0.84 SMN1; SMN2 (0.45) THRBSMN1; SMN2KDM4EMAPTALOX15
SCHEMBL6001470 0.83 CAD (0.44) TGFBR1THRBSMN1; SMN2KDM4EMAPT
SCHEMBL5812827 0.83 THRB (0.41) THRBSMN1; SMN2KDM4EMAPTALOX15
SCHEMBL6001474 0.83 CAD (0.44) TGFBR1THRBSMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3144295-B1 PROCESS FOR THE PREPARATION OF LACOSAMIDE DIVIS LABORATORIES LTD (IN) 2018-12-05 EP claimed
US-20060251597-A1 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J 2006-11-09 US claimed
WO-2024026484-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
WO-2024026479-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
CN-108047268-B 1-aza-5-gera-5-alkyl bicyclo [3.3.3] undecane compound, synthesis method and application 中国科学技术大学 2020-05-01 CN disclosed
WO-2017197014-A2 COMPOSITIONS COMPRISING A POLYMERIC DYE AND A CYCLODEXTRIN AND USES THEREOF SONY CORPORATION (JP) 2017-11-16 WO disclosed
WO-2017173348-A1 ULTRA BRIGHT DIMERIC OR POLYMERIC DYES WITH RIGID SPACING GROUPS SONY CORPORATION (JP) 2017-10-05 WO disclosed
US-9447024-B1 Process for the preparation of lacosamide DIVI'S LABORATORIES LIMITED (IN) 2016-09-20 US disclosed
US-9447024-B1 Process for the preparation of lacosamide DIVI'S LABORATORIES LIMITED (IN) 2016-09-20 US disclosed
US-9303059-B2 Chemoselective enrichment for compound isolation INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-04-05 US disclosed
US-20150315227-A1 PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF UNIVERSITY OF COLORADO BOULDER 2015-11-05 US disclosed
WO-2009004322-A2 DERIVATIVES OF NYSTATIN AND THEIR USE AS ANTIFUNGAL AGENTS BIOSERGEN AS (NO) 2009-01-08 WO disclosed
WO-2006119283-A2 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J (US) 2006-11-09 WO disclosed
US-20060251597-A1 ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE YU RUEY J 2006-11-09 US disclosed
US-6569411-B2 Deodoring, microbiocides, marking odors THE GILLETTE COMPANY 2003-05-27 US disclosed
US-20030018055-A1 Serine carbonates FRATER GEORGE (CH) 2003-01-23 US disclosed
EP-1053223-A1 SERINE CARBONATES Givaudan SA (CH) 2000-11-22 EP disclosed
WO-2000034232-A1 SERINE CARBONATES GIVAUDAN SA (CH) 2000-06-15 WO disclosed
EP-1008587-A1 Serine carbonates Givaudan Roure (International) S.A. (CH) 2000-06-14 EP disclosed
US-4670395-A Enantioselective hydrolysis of N-acylamino acid esters using a combined enzyme system THE STANDARD OIL COMPANY (US) 1987-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018055-A1 Serine carbonates SRR, ME1, TASP1 TGFBR1 2295/4885THRB 3849/4885SMN1; SMN2 1481/4885
US-20150315227-A1 PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF POLN, POLRMT, NUDT21 TGFBR1 4779/4885THRB 3823/4885SMN1; SMN2 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.